Skip to content

Live Events

Live Events

Live Events

Live Events

Library

By pinki shah / May 14, 2022

Speciality

Author / Speaker

Title of Presentation

Type of Media

Event

2024 Event

Clear

Displaying 2,951 - 2,975 of 2,995

«
1
…
117
118
119
120
»

Testicular Cancer: The Old, The New, The Future

Testicular Cancer: The Old, The New, The Future

By: Pasquale W. Benedetto, MD

Strategies to Target Minimal Residual Disease

Strategies to Target Minimal Residual Disease

By: Christine M. Lovly, MD, PhD

Strategies to Target Minimal Residual Disease

Strategies to Target Minimal Residual Disease

By: Christine M. Lovly, MD, PhD

MRD to Decide Perioperative Management in the Era of Immuno-Oncology

MRD to Decide Perioperative Management in the Era of Immuno-Oncology

By: Fred Hirsch, MD

MRD to Decide Perioperative Management in the Era of Immuno-Oncology

MRD to Decide Perioperative Management in the Era of Immuno-Oncology

By: Fred Hirsch, MD

Immunotherapy Related Adverse Reactions

Immunotherapy Related Adverse Reactions

By: Helen Shih, NP, MPH

Immune-Related Adverse Events (irAE) Checkpoint Inhibitors

Immune-Related Adverse Events (irAE) Checkpoint Inhibitors

By: Helen Shih, NP, MPH

ALK-Altered Non-Squamous NSCLC Options and Sequence

ALK-Altered Non-Squamous NSCLC Options and Sequence

By: Jacob Sands, MD

Neoadjuvant Treatment in Thoracic Surgery

Neoadjuvant Treatment in Thoracic Surgery

By: Jae Kim, MD

Systemic Therapies for Mesothelioma

Systemic Therapies for Mesothelioma

By: Jorge E. Gomez, MD

Systemic Therapies for Mesothelioma

Systemic Therapies for Mesothelioma

By: Jorge E. Gomez, MD

ALK Mutant NSCLC

ALK Mutant NSCLC

By: Lyudmila Bazhenova, MD

Oncogene-Driven NSCLC

Oncogene-Driven NSCLC

By: Matthew Gubens MD

What Lies Beyond EGFR, ALK And ROS1 Targeted Therapies?

What Lies Beyond EGFR, ALK And ROS1 Targeted Therapies?

By: Melissa L Johnson, MD

Squamous Cell Carcinoma Standard and Novel Targets

Squamous Cell Carcinoma Standard and Novel Targets

By: Mohamed K Mohamed, MD, PhD

Squamous Cell Carcinoma Standard and Novel Targets.

Squamous Cell Carcinoma Standard and Novel Targets.

By: Mohamed K. Mohamed, MD, PhD

Minimal Residual Disease (MRD) as Detected by Liquid Biopsy: Where are We Going?

Minimal Residual Disease (MRD) as Detected by Liquid Biopsy: Where are We Going?

By: Natasha Leighl, MD

Minimal Residual Disease (MRD) as Detected by Liquid Biopsy: Where are We Going?

Minimal Residual Disease (MRD) as Detected by Liquid Biopsy: Where are We Going?

By: Natasha Leighl, MD

EGFR Mutations: What's Next?

EGFR Mutations: What's Next?

By: Natasha Leighl, MD, FASCO, FRCPS, MMSc

Role of SHP2 Inhibitors Alone or in Combination

Role of SHP2 Inhibitors Alone or in Combination

By: Rachel Sanborn, MD

Role of SHP2 Inhibitors Alone or in Combination

Role of SHP2 Inhibitors Alone or in Combination

By: Rachel Sanborn, MD

Optimal Surgical Approach for Mesothelioma

Optimal Surgical Approach for Mesothelioma

By: Raja Flores, MD

Optimal Surgical Approach for Mesothelioma

Optimal Surgical Approach for Mesothelioma

By: Raja Flores, MD

Thoracic Oncology Session

Thoracic Oncology Session

By: Rita Axelrod, Joshua Bauml, Luis Raez, Janakiraman Subramanian, Primo Lara Jr.

Cancer-related Bleeding and Thrombosis

Cancer-related Bleeding and Thrombosis

By: Anjlee Mahajan, MD

«
1
…
117
118
119
120
»

← Previous View

6619 South Dixie Highway #341
Miami, FL 33143

Phone: 305.663.1628
Email: info@meccinc.com

Userful Links

Live Events

Categories

About Us

Why Subscribe
About Us
Accreditation

© 2025 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok